Connect your AI

Beam Therapeutics BEAM Debt Issuance Costs

Debt Issuance Costs at other companies

Arrowhead ResearchARWR

$18.72M—

MGN

MagniteMGNI

$0-100%

CRISPR TherapeuticsCRSP

$13.53M—

BioCryst PharmaceuticalsBCRX

$4.95M—

BridgeBio PharmaBBIO

——

BioMarin PharmaceuticalsBMRN

——

Other financials

Income statement

Revenue$31.7M+325%

Operating income-$107.2M+10.1%

Net income-$94.3M+12.9%

EPS (diluted)-$0.91+26.0%

Balance sheet

Cash & equivalents$288.3M-45.4%

Total debt$250.8M+58.6%

Total equity$1.2B+3.1%

Total assets$1.5B+0.9%

Cash flow

Operating cash flow-$128.5M-23.7%

CapEx$2.2M-27.2%

Free cash flow-$130.7M-22.2%

Valuation

Market cap$3.42B+24.5%

Profitability

Operating margin-226.6%-90.5pp

Net margin-742.7%—

FCF margin-234%-86.6pp

Returns & leverage

Return on equity-47.1%—

Debt / equity0.2×+0.1×

Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Beam Therapeutics's debt issuance costs?: Beam Therapeutics (BEAM) reported debt issuance costs of $813K in Q1 2026.
What does debt issuance costs mean?: Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.